It’s Clear How Big Money Flows Lift Supernus

Core Insights - SUPN has shown significant growth with a revenue of $165 million in its second-quarter fiscal 2025 earnings report and has launched a new treatment for Parkinson's disease [1] - The stock has increased by 46% this year, indicating strong investor interest, particularly from institutional investors [2][3] - SUPN has a strong fundamental backdrop with an estimated EPS growth of +36.2% this year and a 1-year sales growth rate of +8.9% [4][6] Institutional Support - There has been strong institutional demand for SUPN, evidenced by unusual trading volumes and a history of outlier inflow signals [3][7] - The stock has been a top-rated pick at MoneyFlows for years, reflecting unusual buy pressure and growing fundamentals [5] Financial Performance - SUPN has demonstrated robust financial performance with a remarkable 3-year EPS growth rate of +1,792.4% [6] - The combination of strong fundamentals and significant money flows has historically led to substantial stock price increases [4][7] Price Prediction - Given the historical gains and strong fundamentals, SUPN is considered a potential candidate for a diversified investment portfolio [8]